1019 related articles for article (PubMed ID: 23529568)
1. [Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin].
Wilding JP; Woo V; Soler NG; Pahor A; Sugg J; Rohwedder K; Parikh S;
Dtsch Med Wochenschr; 2013 Apr; 138 Suppl 1():S27-38. PubMed ID: 23529568
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.
Wilding JP; Woo V; Soler NG; Pahor A; Sugg J; Rohwedder K; Parikh S;
Ann Intern Med; 2012 Mar; 156(6):405-15. PubMed ID: 22431673
[TBL] [Abstract][Full Text] [Related]
3. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.
Wilding JP; Woo V; Rohwedder K; Sugg J; Parikh S;
Diabetes Obes Metab; 2014 Feb; 16(2):124-36. PubMed ID: 23911013
[TBL] [Abstract][Full Text] [Related]
4. [Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin].
Nauck M; del Prato S; Meier JJ; Durán-García S; Rohwedder K; Elze M; Parikh SJ
Dtsch Med Wochenschr; 2013 Apr; 138 Suppl 1():S6-15. PubMed ID: 23529570
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial.
Dandona P; Mathieu C; Phillip M; Hansen L; Griffen SC; Tschöpe D; Thorén F; Xu J; Langkilde AM;
Lancet Diabetes Endocrinol; 2017 Nov; 5(11):864-876. PubMed ID: 28919061
[TBL] [Abstract][Full Text] [Related]
6. [Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride].
Strojek K; Yoon KH; Hruba V; Elze M; Langkilde AM; Parikh S
Dtsch Med Wochenschr; 2013 Apr; 138 Suppl 1():S16-26. PubMed ID: 23529567
[TBL] [Abstract][Full Text] [Related]
7. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial.
Bailey CJ; Gross JL; Pieters A; Bastien A; List JF
Lancet; 2010 Jun; 375(9733):2223-33. PubMed ID: 20609968
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: Results of the interim analysis of 16-week double-blind treatment period.
Araki E; Onishi Y; Asano M; Kim H; Ekholm E; Johnsson E; Yajima T
J Diabetes Investig; 2016 Jul; 7(4):555-64. PubMed ID: 27181422
[TBL] [Abstract][Full Text] [Related]
9. Twice-daily dapagliflozin co-administered with metformin in type 2 diabetes: a 16-week randomized, placebo-controlled clinical trial.
Schumm-Draeger PM; Burgess L; Korányi L; Hruba V; Hamer-Maansson JE; de Bruin TW
Diabetes Obes Metab; 2015 Jan; 17(1):42-51. PubMed ID: 25200570
[TBL] [Abstract][Full Text] [Related]
10. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.
Bolinder J; Ljunggren Ö; Johansson L; Wilding J; Langkilde AM; Sjöström CD; Sugg J; Parikh S
Diabetes Obes Metab; 2014 Feb; 16(2):159-69. PubMed ID: 23906445
[TBL] [Abstract][Full Text] [Related]
11. A multicentre, double-blind, placebo-controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add-on therapy in type 2 diabetic patients treated with metformin and dapagliflozin.
Lim S; Lee SH; Min KW; Lee CB; Kim SY; Yoo HJ; Kim NH; Kim JH; Oh S; Won JC; Kwon HS; Kim MK; Park JH; Jeong IK; Kim S
Diabetes Obes Metab; 2024 Jun; 26(6):2188-2198. PubMed ID: 38425186
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial.
Bailey CJ; Morales Villegas EC; Woo V; Tang W; Ptaszynska A; List JF
Diabet Med; 2015 Apr; 32(4):531-41. PubMed ID: 25381876
[TBL] [Abstract][Full Text] [Related]
13. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study.
Weber MA; Mansfield TA; Cain VA; Iqbal N; Parikh S; Ptaszynska A
Lancet Diabetes Endocrinol; 2016 Mar; 4(3):211-220. PubMed ID: 26620248
[TBL] [Abstract][Full Text] [Related]
14. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial.
Bailey CJ; Gross JL; Hennicken D; Iqbal N; Mansfield TA; List JF
BMC Med; 2013 Feb; 11():43. PubMed ID: 23425012
[TBL] [Abstract][Full Text] [Related]
15. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy.
Rosenstock J; Vico M; Wei L; Salsali A; List JF
Diabetes Care; 2012 Jul; 35(7):1473-8. PubMed ID: 22446170
[TBL] [Abstract][Full Text] [Related]
16. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.
Bolinder J; Ljunggren Ö; Kullberg J; Johansson L; Wilding J; Langkilde AM; Sugg J; Parikh S
J Clin Endocrinol Metab; 2012 Mar; 97(3):1020-31. PubMed ID: 22238392
[TBL] [Abstract][Full Text] [Related]
17. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
[TBL] [Abstract][Full Text] [Related]
18. Effects of Dapagliflozin on 24-Hour Glycemic Control in Patients with Type 2 Diabetes: A Randomized Controlled Trial.
Henry RR; Strange P; Zhou R; Pettus J; Shi L; Zhuplatov SB; Mansfield T; Klein D; Katz A
Diabetes Technol Ther; 2018 Nov; 20(11):715-724. PubMed ID: 30222367
[TBL] [Abstract][Full Text] [Related]
19. Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study.
Ji L; Ma J; Li H; Mansfield TA; T'joen CL; Iqbal N; Ptaszynska A; List JF
Clin Ther; 2014 Jan; 36(1):84-100.e9. PubMed ID: 24378206
[TBL] [Abstract][Full Text] [Related]
20. Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin.
Rosenstock J; Mathieu C; Chen H; Garcia-Sanchez R; Saraiva GL
Arch Endocrinol Metab; 2018 Aug; 62(4):424-430. PubMed ID: 30304106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
